TABLE I.

Characteristics of children by age groups

	Total (n = 1037)	≥2 y (n = 559)	<2 y (n = 478)	P value
Sex
Male	469 (45%)	249 (45%)	220 (46%)	.6614
Female	568 (55%)	310 (55%)	258 (54%)
Race/ethnicity
Black	625 (60%)	332 (59%)	293 (61%)	.4025
Hispanic	271 (26%)	155 (28%)	116 (24%)
White	141 (14%)	72 (13%)	69 (14%)
Follow-up time
<12 mo	300 (29%)	149 (27%)	151 (32%)	.3084
≥12-23 mo	450 (43%)	254 (45%)	196 (41%)
>23-35 mo	197 (19%)	109 (19%)	88 (18%)
>35 mo	90 (9%)	47 (8%)	43 (9%)
PFS events
No	811 (78%)	484 (87%)	327 (68%)	<.0001
Yes	226 (22%)	75 (13%)	151 (32%)
Disease progression end point
No event	811 (78%)	484 (87%)	327 (68%)
death	25 (2%)	1 (0%)	24 (5%)
≥2 Opportunistic infections	7 (1%)	4 (1%)	3 (1%)
Weight growth failure	75 (7%)	41 (7%)	34 (7%)
Malignancy	1 (0%)	0 (0%)	1 (0%)
CDC clinical disease category C	12 (1%)	4 (1%)	8 (2%)
All CNS disease progression events:	106 (10%)	25 (4%)	81 (17%)
a. Deterioration of brain growth	65 (6%)	21 (4%)	44 (9%)
b. Deterioration of neurocognitive function	12 (1%)	1 (0%)	11 (2%)
c. Deterioration of neurologic status	29 (3%)	3 (1%)	26 (5%)
Baseline characteristics by age groups
Baseline CD4 (%)
N	1,029	557	472	<.001
Median	24	22.45	26.98
Baseline CD4 count/mm3
N	1,029	557	472	NA*
Median	774.98	596	1269.50
Baseline log10 RNA copies/mL
N	861	467	394	<.001
Median	5.12	4.73	5.64
Baseline cognitive score
N	979	525	454	.274
Median	83	83	83
Baseline WAZ score
N	1037	559	478	<.001
Median	-0.69	-0.29	-1.11

^*Not calculated because younger children generally have higher absolute CD4 counts than older children.